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Background: Clinical Pharmacist should be aware of hematologic tox-
icities from tyrosine kinase inhibitors (TKI) used to treat chronic mye-
logenous leukemia (CML). Drug-drug interactions (DDI) may be prob-
lematic.
Objective: To analyze DDI between TKI and the concomitant medica-
tion.
Setting: Retrospective observational study carried in a tertiary hospi-
tal of Spain.
Method: A bibliographic search was made on the UpToDate®, Lexi-
comp® and Micromedex® software platforms to search for evidence 
on DDI between TKI and the concomitant medication.
Main outcome measure: Number of interactions with respect to sex, 
to number of concomitant drugs, and to TKI used.
Results: A total of 28 patients were analyzed. 78.6% of patients had 
medication associated with the TKI. There was a total of 50 significant 
DDI, out of a total of 128 drugs, so the risk of having interaction in the 
study population was 39.1%. Regarding the management of the inter-
actions by the hematologist and the acceptance of the pharmaceutical 
intervention: 10 patients experienced 14 high-level interactions. Of 
these the doctor knew 50% and had performed intervention in all cas-
es: modify the treatment in 28.6%, consulted with service responsible 
for treatment in 42.8% and spaced the intake of drugs in 28.6%. It is 
important to periodically review concomitant medication and to have 
a strategy to manage interactions. The role of the clinical pharmacist 
is essential in communication with the patient, assessment of treat-
ments, detecting potential interactions and disseminating information 
among the multidisciplinary team.
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Introduction
In recent years, advances in the treatment of cancer 
have led to the emergence of numerous oral anti-
neoplastic drugs. The oral route is consolidated in 
the first-line treatments of some carcinomas, as it 
has been shown that the disease-free survival and 
overall survival, as well as the toxicity profiles, are 
not different from those of the parenteral route1. 
However, drug interactions are common and may be 
problematic. Concomitant use with moderate CYP3A 
inhibitors, strong or moderate CYP3A inducers, gly-
coprotein-P (P-gp) inhibitors, or narrow therapeutic 
index P-gp substrates should be avoided. Therefore, 
the pharmacodynamic characteristics of drugs do 
not vary over time, but plasma and tissue concen-
trations, as well as efficacy may be influenced as a 
result of concomitant treatments or specific eating 
habits2, 3.
In this scenario, new challenges have been posed 
for the clinical pharmacist, specialized in the area of 
oncological consultation, and in charge of the care of 
these patients such as the monitoring of therapeutic 
adherence, and management of adverse effects and 
interactions or safe handling of toxic waste at home. 
The onco-hematological patient is especially suscep-
tible to drug interactions, as he often receives one or 
more antineoplastic agents, along with concomitant 
medications, to alleviate the pain or adverse effects 
of the chemotherapy itself. In addition, there are 
several factors derived from the disease that predis-
pose patients to interactions, such as poor absorp-
tion, malnutrition, liver or kidney damage4.
The most concerning interactions are those whose 
consequences are detrimental for the patient expo-
sure to the drug, either because it is increased caus-
ing adverse effects, or because exposure is dimin-
ished causing an inadequate therapeutic response5. 
In the case of antineoplastic drugs, this can lead to 
treatment failure or loss of scarce therapeutic op-
tions available6, thus compromising patient’s safety7.
Riechelmann et al. concluded that 67% of hospi-
talized cancer patients were at risk of experiencing a 
drug interaction8. The factors that predispose them 
to this include the number of drugs involved in their treatment9, frequent use of alternative medicines, 
comorbidities, organic deterioration that affects the 
processes of metabolization and excretion of the 
drugs, and finally, the fact that a large number of the 
recently commercialized cytostatics have not un-
dergone extensive premarketing studies that allow 
proper drug interactions analysis10.
This study expresses oral cytostatics involved in 
the treatment of chronic myeloid leukemia (CML). 
The introduction of tyrosine kinase inhibitors 
(TKIs) revolutionized the management of CML11, 12, 
improving the 10-year overall survival from ~20% 
to 80-90%. In some patients, expected survival is in-
distinguishable from that of the general population 
13. These are the first drugs with a specific therapeu-
tic target: the BCR-ABL fusion gene. The first TKI 
to appear was Imatinib. Despite the good results of 
studies with this drug, there is a group of patients in 
whom it is not possible to use Imatinib, either due 
to intolerance, adverse reactions, suboptimal effects 
or resistance to the drug. The options available after 
Imatinib resistance at maximum doses are the sec-
ond-generation TKIs include Dasatinib and Nilotin-
ib.
It is important to consider potential drug-drug in-
teractions between TKIs and substrates, inhibitors 
or inducers of the CYP3A4 isoform and the P-gp. Re-
cent studies revealed that concomitant prescription 
of drugs that can inhibit the effectiveness of protein 
Conclusion: All patients who are prescribed oral antineoplastic drugs 
are provided patient education materials about TKI, which include pos-
sible interactions. Any changes in the patient’s medications prompt a 
review for DDI.
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kinase inhibitors can vary between 23 and 57%, and 
drugs that can increase their toxicity between 25 
and 74%10, 14, 15.
Patients with CML usually take several medica-
tions simultaneously with their oncological therapy 
therefore, taking into account the risks of polyphar-
macy, it is possible that there are potential phar-
macological interactions between their oncological 
treatment and the rest of medications. To assess the 
impact of these interactions, we intend to carry out 
a study in patients treated with TKIs in a third level 
clinical university hospital.
The aim of this study was to analyze the presence 
of pharmacological interactions between TKIs and 
the concomitant medications used in patients with 
CML, and to investigate the influence of clinical 
pharmacist’s interventions.
Material and methods
A retrospective observational study in which 28 
adult patients diagnosed with CML and treated with 
TKI were selected who attended the Clinical Phar-
macy Service of a tertiary level Clinical University 
Hospital from October 1, 2016 to October 1, 2017. 
The data on the treatment were obtained retrospec-
tively from the individual dispensing module of the 
Dominion Farmatools® program. The following 
variables related to the patients were collected: age, 
sex, type and dose of antineoplastic drug, character-
istics and number of concomitant non-antineoplas-
tic medications and number, level and type of drug-
drug interactions noted. The collected information 
included additional medication patients could be 
taking for other indications such us medications pre-
scribed by the GP/other Doctors/specialists. To de-
tect the possible interactions between their regular 
mediations and oncological therapy, a bibliographic 
search was carried out on the UpToDate® (and Lex-
icomp® to detect DDIs) and Micromedex® comput-
er platforms and the information obtained with the 
technical data sheets of the drugs was completed. 
The interactions were classified according to their 
severity, following the classification of Lexicomp® 
database (LexiComp, Inc, Hudson, Ohio, 2010) and 
DRUG-REAX System® (Thomson Reuters, Green-
wood Village, Colo, USA, 2010). Each drug-drug in-
teraction is assigned a risk rating of A, B, C, D, or X. 
Monographs rated X, D or C indicate situations that 
will likely demand a clinician’s attention.
- Level of interaction X: significant interaction, 
avoid combination. The risks associated with the 
concomitant use of these two drugs normally out-
weigh the benefits. It is a contraindicated drug com-
bination.
- Level of interaction D: significant interaction, 
consider therapy modification. A patient-specific 
evaluation should be conducted to determine if the 
benefits of such treatment outweigh the risks. Ac-
tions such as exhaustive monitoring, dose changes 
or use of alternative drugs should be carried out to 
obtain benefits or decrease the toxicity resulting 
from the concomitant use of said drugs.
- Level of interaction C: significant interaction, 
monitor therapy. Normally, the benefits of the con-
comitant use of these drugs outweigh the risks. In 
any case, a monitoring plan must be carried out to 
detect potential adverse events. Dose adjustments 
may be necessary in one or both drugs in a minority 
of patients.
Potential interactions were identified, as well as 
their prevalence and the risk that this could pose to 
the patient. They were also classified according to 
the type of interaction in pharmacokinetics, phar-
macodynamics or others and within each of them an 
increase or decrease in dose was expected.
Once all the information was collected, the spe-
cialist responsible for the patients was informed 
about the most relevant interactions. A detailed re-
view was done for each patient, jointly between the 
hematologist and the pharmacist using the clinical 
history, evolution of the analytical data, and medi-
cation changes, in order to design a clinical decision 
for each type of interaction in each patient. The clin-
ical significance of these interactions was recorded 
by the hematologist and the acceptance and utility 
of the pharmaceutical intervention performed was 
evaluated.
The quantitative variables were summarized with 
mean and standard deviation or median and range, 
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and the qualitative variables with percentages. 
Statistical analysis was performed in the group of 
patients who were prescribed concomitant treat-
ment, and the patients were grouped according to 
whether they had relevant interactions between the 
antineoplastic drugs and their concomitant drugs. 
Differences in sex, concomitant treatment (greater 
or lesser than 5 drugs) and TKI used were evaluated 
using the chi-square test (χ2). Statistical analysis was 
carried out with the statistical package SPSS 21.0 for 
Windows (License of the University of Zaragoza).
Ethics approval: A study with initial protocol was 
prepared to submit to explore confirmation by the 
Clinical Research Ethics Committee. Enrollment, 
medical, and drug files were linkable based on an 
encrypted patient identification number. The use 
and analysis of de-identified administrative claims 
or limited data sets; was considered exempt from 
review by an Institutional Review Board (IRB), as 
de-identified information requires personal health 
information (PHI) waiver of authorization.
Results
A total of 28 patients with CML treated with a TKI 
were analyzed. 60.7% were males with an average 
age of 56.5 ± 14.2 years, and only 42.8% of the pa-
tients were older than 60 years. 39.3% of patients 
were treated with a first-generation TKI (Imatinib), 
while 39.3% were being treated with Dasatinib, and 
21.4% of patients with Nilotinib.
78.6% of the patients had concomitant medica-
tions that included analgesics / opioids, anxiolytics 
/ hypnotics / sedatives and antihypertensives, fol-
lowed by proton pump inhibitors (PPIs). Table 1 de-
scribes the frequencies of prescribed non-antineo-
plastic drugs.
The median of concomitant drugs prescribed was 
4 (range 0 to 16). 21.4% of patients did not take 
any additional drugs, 39.3% had 1 to 5 concomitant 
drugs and 39.3% had ≥5 prescribed non-antineo-
plastic drugs.
A total of 50 TKI- no TKI interactions were record-
ed. These interactions occurred in 20 patients out 
of 28, who took a total of 128 drugs, so the risk of 
interactions in the study population was 39.1%. Of 
the total interactions detected, 72.6% were poten-
tial interactions (level C) in which a dose adjustment 
is not necessary but precaution and monitoring of 
adverse events is recommended, 15.1% were level 
D, in which the modification of the therapy is rec-
ommended, while the amount of contraindicated 
interactions (level X) was 12.2%, in which it was 
recommended to avoid this combination of drugs. 
The median of interactions was 1 (0-5). Interactions 
almost entirely were of pharmacokinetic nature 
(90.7%), of these 87.4% involved a possible increase 
in concomitant drug concentrations, due to the in-
hibitory nature of TKI and only 12.6% a possible 
decrease in the concentration of TKI due to interfer-
ence in absorption (antacids and PPIs). The drugs 
with the highest number of interactions were anal-
gesic / opioid, antihypertensive and antipsychotic 
potential (Table 2).
In patients treated with Imatinib, 34.2% of the 
concomitant treatment could result in an inter-
action. Of these interactions, 84.6% were of level 
C, due to the moderate inhibition of cytochromes 
CYP3A4 (31.8%) and CYP2D6 (27.3%) and of the 
P-gp (4.5%). 3.8% were level D, and 11.6% were lev-
el X. In this last group, interaction with Metamizole 
(dipyrone) stands out, as it can increase adverse re-
actions such as agranulocytosis and pancytopenia.
In case of Dasatinib, 48.0% of concomitant drugs 
had the possibility of interacting with TKIs. Of these 
interactions, 75.0% were level C, due mainly to the 
inhibition of cytochrome CYP3A4 (44.4%) and the 
increase in the antiplatelet effect (33.3%). 8.3% 
were level D and 16.7% level X, highlighting the in-
teraction with PPIs, which significantly reduce the 
absorption of Dasatinib, thus reducing its plasma 
concentration.
Finally, amongst the patients on Nilotinib, 44.4% 
of concomitant drugs had some type of interaction. 
58.3% of the interactions were of level C, 33.3% 
were of level D, due to their interaction with antac-
ids and divalent ions (66.7%) and 8.4% of level X, 
due to the high risk of prolongation of the QT seg-
ment on ECG and risk of developing cardiac toxicity, 
as with Quetiapine.
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In the overall statistical analysis, there were no 
significant differences in the number of interactions 
with respect to sex (p = 0.386). There were also no 
significant differences in the frequency of relevant 
interactions between patients who had less than 
5 concomitant drugs and more than 5 drugs (p = 
0.603). As for the TKI used, no significant differenc-
es were found in patients who used first generation 
(Imatinib) or second generation TKI (Dasatinib / 
Nilotinib) (p = 0.174) although there is a tendency 
to have more interactions with the second genera-
tion TKIs.
Regarding the management of the interactions by 
the hematologist and the acceptance of the pharma-
ceutical intervention: 10 patients experienced 14 
high-level interactions (D or X). Of these the doctor 
managed 50% of the interactions and had made 
intervention in all cases: modify the treatment in 
28.6%, interconsultation with service responsi-
ble for treatment in 42.8% and space the taking of 
drugs in 28.6 %. With the other 50% of the inter-
actions an individualized pharmaceutical interven-
tion was carried out and recommendations included 
interconsultation to the service responsible for the 
treatment (14.3%), space the taking of the drugs 
(42.8%), monitor possible adverse effects due to the 
interaction (14.3%) and modify / reduce treatment 
(28.6%). All the proposals were accepted by the re-
sponsible physician.
Discussion
In the present study, the estimation of the risk of 
presenting with clinically relevant interactions be-
tween TKI and non-TKI drugs was lower than that 
described in the literature8,9. The percentage of in-
teractions that increase concomitant drug concen-
trations was higher than that of a study presented 
in the USA by Bowlin et al. in 201316, while the per-
centage of interactions that decrease the concen-
tration of TKI and thus its effectiveness, was lower 
than that of Browlin study. The cause of these differ-
ences may be the limited sample of patients and the 
fact that the study has been done only for the TKIs 
that treat CML. Other studies confirm that greater 
the number of concomitant drugs in patients diag-
nosed with CML on TKIs, greater the risk of interac-
tions [5,6], On the other hand, in the current study 
no significant differences were observed regarding 
the frequency of relevant interactions between pa-
tients who had less than 5 concomitant drugs and 
more than 5 drugs. This is because the interactions 
between non-antineoplastic drugs have not been in-
cluded. No differences were observed in interactions 
when administering first generation or second gen-
eration TKI, since pharmacologically no metabolic 
profile more is susceptible to suffering interactions 
than another.
The analgesic and sedative drugs together with 
the antihypertensive drugs were the most frequent-
ly prescribed in the patients included in the study. 
Pain, insomnia and depression were one of the most 
frequent comorbidities in the cancer population 
and, therefore, analgesic and psychiatric drugs are 
the most frequently prescribed drugs. The concomi-
tant drugs involved in the interactions were analge-
sics, antihypertensives and antipsychotics, followed 
very closely by anxiolytic drugs, PPIs and blood glu-
cose lowering drugs.
Regarding the joint assessment with the respon-
sible physician, the professionals’ concern about 
the interactions of this group of drugs was demon-
strated and, due to the lack of time in the consul-
tation or the limitation in access to search tools 
and databases, cannot be properly addressed by 
the hematologist. The intervention of the clinical 
pharmacist both at the beginning of the treatment 
and in successive reviews of medication could help 
avoid adverse events and even avoid the change to 
second generation TKIs, which sometimes occurs 
due to intolerances or adverse events of unknown 
origin, thus improving adherence. With this inter-
vention, the real need of another drug, molecular 
response of the patient, clinical situation and, in 
some cases, the plasma levels of TKI, would help to 
predict the result of the interaction. Thus, the per-
sonalized pharmacotherapeutic follow-up of the 
hematological patient should lead to collaboration 
with the hematologist and other health profession-
als forming part of a multidisciplinary team.
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Table 1. Frequencies of prescribed non-antineoplastic drugs
PRESCRIBED NON-ANTINEOPLASTIC DRUGS DRUGS ( N=128) % (N)
ANALGESICS / OPIOIDS 14.8 % (19)
ANXIOLYTICS / HYPNOTICS / SEDATIVES 12.5 % (16)
ANTIHYPERTENSIVES 10.1 % (13)
PROTON PUMP INHIBITORS 9.4 % (12)
ANTIDEPRESSIVES 7.8 % (10)
LIPID MODIFYING AGENTS 7.0 % (9)
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 6.2 % (8)
ANTIPSYCHOTICS / NEUROLEPTICS 6.2 % (8)
STEROIDS 5.5 % (7)
ANTICOAGULANTS 5.5 % (7)
ANTIHISTAMINES FOR SYSTEMIC USE 4.7 % (6)
ANTIBACTERIALS 3.1 % (4)
DIURETICS 2.3 % (3)
ANTICONVULSIVANTS 1.6 % (2)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 1.6 % (2)
ANTIVIRALS 0.8 % (1)
ANTIPARKINSONIANS 0.8 % (1)
In the present study, most of the interactions were 
pharmacokinetic, due to substrates, inhibitors or in-
ducers of the CYP3A4, CYP2D6 and P-gp isoforms, 
confirming the information published in a review 
carried out in 20146.
The work carried out presents a series of perfectly 
defined limitations. Firstly, the sample size is limit-
ed; resulting directly from the population of adult 
patients with treated CML in the geographic area of 
study. Secondly, as it is a retrospective analysis, there 
may be loss of information in the variables collect-
ed from the computerized medical record, since it 
is possible that the concomitant treatment in pro-
gress was not updated correctly in some cases. As 
the study was retrospective, there is also potential 
that the patient is no longer taking the interacting 
medication. Thirdly, interaction data was not always 
available in the databases for the different drug com-
binations. Fourthly, the study has been carried out 
for the TKIs that treat CML, there are other TKIs with 
other indications and most of the studies consulted 
analyze all the TKIs, so they cannot be compared 
directly. Finally, the interaction rates have been un-
derestimated since the interactions between the an-
tineoplastic drugs themselves or among the non-an-
tineoplastic drugs have not been included. To sum 
up, this is a small study which does provide evidence 
of the benefit of pharmacist role in reviewing pa-
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tients who are taking TKIs for CML
This study demonstrates that oral antineoplas-
tics require pharmaceutical interventions aimed at 
preventing and / or minimizing the risk of toxicity 
or decreased efficacy due to interactions with oth-
er medications. Many of the drug interactions in 
oncology are not recognized as such since they are 
masked by some symptoms of the pathology itself 
and are even confused with the toxicity inherent to 
the use of antineoplastic drugs. Therefore, before in-
troducing a new drug in onco-hematological patient 
therapy, it is important to question the real need for 
it, assessing possible safer alternatives.
The Clinical Pharmacy Services have shown that 
by means of the pharmaceutical intervention, the 
risk of an adverse event caused by a pharmacolog-
ical DDI can be reduced by 25.9 %17. This context 
makes the act of the pharmaceutical interview a 
valuable tool to detect and manage interactions 
involving oral antineoplastic drugs18. Therefore, 
patients with complex treatments and a high risk 
of potential pharmacotherapeutic problems (that 
may compromise the effectiveness and safety of 
the treatment) may benefit from this Service. In 
this context, clinical pharmacists have played a 
fundamental role in pharmacotherapeutic care 
and monitoring of the external onco-hematologi-
cal patient.
This work could be used in the future for devel-
opments of the Clinical Pharmacy Service. Another 
possible future guideline with these drugs, given 
the wide possibility of pharmacological interaction, 
would be their pharmacokinetic monitoring in rou-
tine clinical practice, since target concentrations are 
available in terms of efficacy, and target concentra-
tions to ensure the safety of the treatment19, 20.
With this study we conclude that administration 
of concomitant drugs causes a potential risk of ex-
periencing DDIs. In addition, it is important to pe-
riodically review the concomitant medication and 
have a strategy to manage those interactions and 
avoid them. And that the role of the pharmacist is 
fundamental in the communication with the pa-
tient, assessment of their treatment, and detection 
Table 2. No tyrosine kinase inhibitors (TKI) implicated in interactions
NON-ANTINEOPLASTIC DRUGS INTERACTIONS ( N=50) % (N)
ANALGESICS / OPIOIDS 20 % (10)
ANTIHYPERTENSIVES 16 % (8)
ANTIPSYCHOTICS / NEUROLEPTICS 16 % (8)
ANXIOLYTICS / HYPNOTICS / SEDATIVES 10 % (5)
PROTON PUMP INHIBITORS 8 % (4)
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 8 % (4)
ANTICOAGULANTS 6 % (3)
ANTIACIDS 6 % (3)
STEROIDS 4 % (2)
ANTIBACTERIALS 2 % (1)
LIPID MODIFYING AGENTS 2 % (1)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 2 % (1)
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of potential interactions and the dissemination of 
medication information among the multidiscipli-
nary team.
Conclusions
All patients who are prescribed oral antineoplas-
tic drugs should be provided written or electronic 
patient education materials about their treatment 
before or at the time of prescription. Patient educa-
tion includes: the preparation, administration, and 
disposal of their antineoplastic drug; concurrent 
cancer treatment and supportive care medications/
measures (when applicable); possible drug/drug 
and drug/food interactions; and the plan for missed 
doses. At each clinical encounter, staff must review 
the patient’s current medications including over the 
counter medications and complementary and alter-
native therapies. Any changes in the patient’s med-
ications prompt, should review for drug-drug inter-
actions, as well as communication the prescribing 
physicians. 
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